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Insufficient production of the hormone insulin by pancreatic β cells results in diabetes. In this 
issue, Sumara et al. (2009) report key roles for the protein kinases p38δ and PKD1 in the regulation 
of insulin secretion as well as in the survival of pancreatic β cells.Diabetes, a leading cause of death in 
developed countries, is a metabolic 
disease characterized by the loss of 
glucose homeostasis due to defec-
tive insulin function. There are two 
main types of diabetes depending on 
whether the defect results from insuf-
ficient insulin production by the pan-
creatic β cells (type 1) or is due to 
insensitivity of peripheral tissues (such 
as skeletal muscle, liver, or adipose tis-
sue) to secreted insulin (type 2). The 
decreased insulin sensitivity of periph-
eral tissues in type 2 diabetes, which 
accounts for ?90% of all cases of the 
disease, is initially compensated for by 
increased secretion of insulin by the β 
cells of the pancreas. However, as the 
disease progresses, elevated insulin 
secretion leads to β cell damage and 
eventual loss of insulin production. In 
this issue of Cell, Sumara et al. (2009) 
define a new regulatory module involv-
ing the p38 mitogen-activated pro-
tein kinase (MAPK) family member 
p38δ (also referred to as SAPK4 and 
MAPK13) and protein kinase D1 (PKD1) 
in controlling insulin secretion and β 
cell survival.
The role of the p38 MAPK pathway 
in diabetes is not well defined, although 
p38 MAPK phosphorylation is increased 
in the skeletal muscle and adipocytes 
of patients with type 2 diabetes and 
this signaling pathway has been sug-
gested to contribute to the pathogenesis 
of insulin resistance (Koistinen et al. 
2003, Carlson et al., 2003). The mam-
malian p38 MAPK family comprises 
four members (p38α, p38β, p38γ, and 
p38δ) that are encoded by different 
genes. Of these four kinases, p38α is widely expressed in different tissues 
and the most intensively studied. Tar-
geted gene-inactivation experiments 
in mice have revealed an essential role 
for p38α in formation of the placenta; 
p38α inactivation in adult mice has 
also uncovered important functions for 
this protein kinase in tissues such as 
liver and lung (Hui et al. 2007; Ventura 
et al. 2007). In contrast, much less is 
known about the other three p38 MAPK 
family members. Mice lacking p38β, 
Figure 1. PKD1 and p38δ Regulate Pancreatic β Cell Function
PKD1 may be activated by high glucose or by signals downstream of G protein-coupled receptors and 
tyrosine kinase receptors. Upon activation, PKD1 translocates to the nucleus to regulate DNA synthesis 
and gene expression or to the Golgi to modulate fission of vesicles from the trans-Golgi network (TGN) 
and insulin secretion. In addition, PKD1 also controls cell survival. Oxidative stress triggers the activation 
of p38δ, which in turn phosphorylates and inhibits PKD1, inducing the apoptosis of β cells. It is not clear 
how p38δ is normally activated in pancreatic β cells to control insulin exocytosis through PKD1 regula-
tion, but this may involve positive and negative regulation by cytokine receptors and G protein-coupled 
receptors, respectively. Circulating insulin secreted by pancreatic β cells acts on peripheral tissues such 
as skeletal muscle, adipose tissue, and liver.Cell 136, January 23, 2009 ©2009 Elsevier Inc. 209
p38γ, or p38δ are viable and show no 
obvious phenotypes (Sabio et al. 2005; 
Beardmore et al. 2005), although this 
could be explained by possible func-
tional redundancies among the four 
kinases. The p38β kinase is closely 
related to p38α but is expressed at 
very low levels with unknown contri-
butions to p38 MAPK signaling. The 
remaining two p38 MAPK family mem-
bers have more restricted expression 
patterns, with p38δ expressed mainly 
in the pancreas, kidney, testes, and 
small intestine and p38γ expressed in 
skeletal muscle, suggesting that they 
might have more specialized functions 
(Goedert et al. 1997).
Given the high level of p38δ expres-
sion in the pancreas where insulin-
producing β cells reside, Sumara et al. 
investigated whether this protein kinase 
plays a role in glucose homeostasis. 
Strikingly, p38δ-deficient mice have 
improved glucose tolerance, which cor-
relates with enhanced insulin exocytosis 
by pancreatic β cells. Insulin secretion 
is mediated by the exocytosis of secre-
tory vesicles that contain the hormone 
and derive from the trans-Golgi net-
work (Figure 1). To determine how p38δ 
may be affecting insulin exocytosis, the 
authors used a mass spectrometry-
based proteomic approach and identi-
fied PKD1 as a protein that associates 
with a constitutively active mutant form 
of p38δ in cultured human cells. PKD1 is 
known to positively regulate secretion in 
neuroendocrine cells and promotes the 
fission of vesicles destined for exocy-
tosis at the plasma membrane from the 
trans-Golgi network (Bard and Malho-
tra, 2006). Consistent with PKD1 being 
the target of p38δ during regulation of 
insulin exocytosis, p38δ appears to reg-
ulate trans-Golgi network fission events 
in cultured murine β cells. In addition, 
pharmacological inhibition of PKD1 
activation restores insulin secretion by 
β cells as well as glucose tolerance in 
p38δ-deficient mice.
The authors find that p38δ phos-
phorylates PKD1 on two residues 
(Ser397 and Ser401 in human PKD1) 
in vitro. Mutation analysis further 
suggests that these phosphorylation 
events reduce PKD1 activity. Consis-210 Cell 136, January 23, 2009 ©2009 Elsevtent with this, higher levels of active 
PKD1 are detected in the pancreas of 
p38δ-deficient mice compared with 
wild-type mice. Moreover, short hair-
pin RNA-mediated downregulation of 
p38δ expression in cultured mouse 
β cells also increases PKD1 activity. 
Taken together, the results suggest 
that p38δ negatively regulates insulin 
secretion by decreasing PKD1 activ-
ity and thus inhibiting PKD1-directed 
fission of insulin-containing vesicles 
from the trans-Golgi network destined 
for exocytosis. How phosphorylation 
of PKD1 by p38δ limits PKD1 activity 
still remains unclear. Phosphorylation 
by p38δ could directly modulate PKD1 
kinase activity or alter its subcellular 
localization. Alternatively, phospho-
rylation by p38δ could prevent the 
association of PKD1 with diacylglyc-
erol (which recruits the kinase to the 
trans-Golgi network) or could preclude 
PKD1 activation by protein kinase Cη. 
Regardless of the precise mechanism 
of PKD1 regulation by p38δ, the work 
of Sumara and colleagues strongly 
suggests that the p38δ-PKD1 module 
is a key regulator of insulin exocytosis 
in pancreatic β cells.
Interestingly, p38δ seems to be an 
important regulator of other processes 
related to the pathogenesis of diabe-
tes, namely insulin resistance and β 
cell death. Sumara et al. observe that 
p38δ-deficient mice on a high-fat diet 
develop less severe peripheral insulin 
resistance than do wild-type mice fed 
the same diet. Furthermore, the pan-
creatic β cells of the p38δ-deficient 
mice are less sensitive to oxidative 
stress caused by the drug streptozo-
tocin. Increased PKD1 activity in the 
absence of p38δ-imposed inhibition 
appears to be directly mediating this 
protective effect, as treatment of the 
p38δ-deficient mice with a drug that 
impairs PKD1 activation results in the 
renewal of β cell susceptibility to oxi-
dative stress. How PKD1 activity may 
protect pancreatic β cells against 
apoptosis induced by oxidative stress 
is unknown, although it has been pro-
posed that PKD1 mediates the activa-
tion of the prosurvival transcription 
factor NF-κB, which is induced by oxi-ier Inc.dative stress (Storz and Toker, 2003). 
Thus, the regulation of PKD1 appears 
to be a critical function of p38δ activity 
in vivo both in the context of increased 
insulin secretion induced by high glu-
cose and in β cell survival.
Beyond advancing our understand-
ing of the physiological role of the 
p38δ MAPK, the work of Sumara et 
al. suggests that the signaling module 
of p38δ and PKD1 may be a potential 
therapeutic target for human diabetes. 
Future studies will need to elucidate 
how p38δ activity is regulated during 
normal pancreatic β cell function and 
the molecular mechanisms underlying 
PKD1 regulation of vesicle trafficking 
and β cell survival. Whether the regu-
lation of PKD1 activity by p38δ could 
be a general mechanism for controlling 
macromolecule secretion as well as 
protein transport from the trans-Golgi 
network to the cell surface in nonse-
cretory cells remain exciting questions 
for further exploration.
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